Global Neurological Drugs Market Growth 2026-2032
The global Neurological Drugs market size is predicted to grow from US$ 141040 million in 2025 to US$ 234460 million in 2032; it is expected to grow at a CAGR of 7.7% from 2026 to 2032.
Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.
United States market for Neurological Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Neurological Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Neurological Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Neurological Drugs players cover Pfizer, Ely Lilly, Actavis, Mylan, Randox, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Neurological Drugs Industry Forecast” looks at past sales and reviews total world Neurological Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Neurological Drugs sales for 2026 through 2032. With Neurological Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurological Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.
United States market for Neurological Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Neurological Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Neurological Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Neurological Drugs players cover Pfizer, Ely Lilly, Actavis, Mylan, Randox, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Neurological Drugs Industry Forecast” looks at past sales and reviews total world Neurological Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Neurological Drugs sales for 2026 through 2032. With Neurological Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurological Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Non-prescription drugs
- Prescription
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Ely Lilly
- Actavis
- Mylan
- Randox
- Intellipharmaceutics
- Astrazeneca
- Lundbeck
- Allergan
- GSK
- Otsuka Pharmaceutical
- Takeda
- NHU Group
- Shionogi
- APOTEX
- North China Pharmaceutical
- Harbin Pharmaceutical Co., Ltd.
- Lukang Pharmaceutical
- Kelun Pharmaceutical
- Kehua Biology
- What is the 10-year outlook for the global Neurological Drugs market?
- What factors are driving Neurological Drugs market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Neurological Drugs market opportunities vary by end market size?
- How does Neurological Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurological Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Neurological Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Neurological Drugs by Country/Region, 2021, 2025 & 2032
2.2 Neurological Drugs Segment by Type
2.2.1 Non-prescription drugs
2.2.2 Prescription
2.2.3 Neurological Drugs Sales by Type
2.2.3.1 Global Neurological Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Neurological Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Neurological Drugs Sale Price by Type (2021-2026)
2.3 Neurological Drugs Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Neurological Drugs Sales by Application
2.3.3.1 Global Neurological Drugs Sale Market Share by Application (2021-2026)
2.3.3.2 Global Neurological Drugs Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Neurological Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Neurological Drugs Breakdown Data by Company
3.1.1 Global Neurological Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Neurological Drugs Sales Market Share by Company (2021-2026)
3.2 Global Neurological Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Neurological Drugs Revenue by Company (2021-2026)
3.2.2 Global Neurological Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Neurological Drugs Sale Price by Company
3.4 Key Manufacturers Neurological Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurological Drugs Product Location Distribution
3.4.2 Players Neurological Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEUROLOGICAL DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neurological Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Neurological Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Neurological Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Neurological Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Neurological Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Neurological Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Neurological Drugs Sales Growth
4.4 APAC Neurological Drugs Sales Growth
4.5 Europe Neurological Drugs Sales Growth
4.6 Middle East & Africa Neurological Drugs Sales Growth
5 AMERICAS
5.1 Americas Neurological Drugs Sales by Country
5.1.1 Americas Neurological Drugs Sales by Country (2021-2026)
5.1.2 Americas Neurological Drugs Revenue by Country (2021-2026)
5.2 Americas Neurological Drugs Sales by Type (2021-2026)
5.3 Americas Neurological Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurological Drugs Sales by Region
6.1.1 APAC Neurological Drugs Sales by Region (2021-2026)
6.1.2 APAC Neurological Drugs Revenue by Region (2021-2026)
6.2 APAC Neurological Drugs Sales by Type (2021-2026)
6.3 APAC Neurological Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neurological Drugs by Country
7.1.1 Europe Neurological Drugs Sales by Country (2021-2026)
7.1.2 Europe Neurological Drugs Revenue by Country (2021-2026)
7.2 Europe Neurological Drugs Sales by Type (2021-2026)
7.3 Europe Neurological Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurological Drugs by Country
8.1.1 Middle East & Africa Neurological Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Neurological Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Neurological Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Neurological Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurological Drugs
10.3 Manufacturing Process Analysis of Neurological Drugs
10.4 Industry Chain Structure of Neurological Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurological Drugs Distributors
11.3 Neurological Drugs Customer
12 WORLD FORECAST REVIEW FOR NEUROLOGICAL DRUGS BY GEOGRAPHIC REGION
12.1 Global Neurological Drugs Market Size Forecast by Region
12.1.1 Global Neurological Drugs Forecast by Region (2027-2032)
12.1.2 Global Neurological Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Neurological Drugs Forecast by Type (2027-2032)
12.7 Global Neurological Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Neurological Drugs Product Portfolios and Specifications
13.1.3 Pfizer Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Ely Lilly
13.2.1 Ely Lilly Company Information
13.2.2 Ely Lilly Neurological Drugs Product Portfolios and Specifications
13.2.3 Ely Lilly Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Ely Lilly Main Business Overview
13.2.5 Ely Lilly Latest Developments
13.3 Actavis
13.3.1 Actavis Company Information
13.3.2 Actavis Neurological Drugs Product Portfolios and Specifications
13.3.3 Actavis Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Actavis Main Business Overview
13.3.5 Actavis Latest Developments
13.4 Mylan
13.4.1 Mylan Company Information
13.4.2 Mylan Neurological Drugs Product Portfolios and Specifications
13.4.3 Mylan Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Mylan Main Business Overview
13.4.5 Mylan Latest Developments
13.5 Randox
13.5.1 Randox Company Information
13.5.2 Randox Neurological Drugs Product Portfolios and Specifications
13.5.3 Randox Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Randox Main Business Overview
13.5.5 Randox Latest Developments
13.6 Intellipharmaceutics
13.6.1 Intellipharmaceutics Company Information
13.6.2 Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
13.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Intellipharmaceutics Main Business Overview
13.6.5 Intellipharmaceutics Latest Developments
13.7 Astrazeneca
13.7.1 Astrazeneca Company Information
13.7.2 Astrazeneca Neurological Drugs Product Portfolios and Specifications
13.7.3 Astrazeneca Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Astrazeneca Main Business Overview
13.7.5 Astrazeneca Latest Developments
13.8 Lundbeck
13.8.1 Lundbeck Company Information
13.8.2 Lundbeck Neurological Drugs Product Portfolios and Specifications
13.8.3 Lundbeck Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Lundbeck Main Business Overview
13.8.5 Lundbeck Latest Developments
13.9 Allergan
13.9.1 Allergan Company Information
13.9.2 Allergan Neurological Drugs Product Portfolios and Specifications
13.9.3 Allergan Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Allergan Main Business Overview
13.9.5 Allergan Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Neurological Drugs Product Portfolios and Specifications
13.10.3 GSK Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 Otsuka Pharmaceutical
13.11.1 Otsuka Pharmaceutical Company Information
13.11.2 Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Otsuka Pharmaceutical Main Business Overview
13.11.5 Otsuka Pharmaceutical Latest Developments
13.12 Takeda
13.12.1 Takeda Company Information
13.12.2 Takeda Neurological Drugs Product Portfolios and Specifications
13.12.3 Takeda Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Takeda Main Business Overview
13.12.5 Takeda Latest Developments
13.13 NHU Group
13.13.1 NHU Group Company Information
13.13.2 NHU Group Neurological Drugs Product Portfolios and Specifications
13.13.3 NHU Group Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 NHU Group Main Business Overview
13.13.5 NHU Group Latest Developments
13.14 Shionogi
13.14.1 Shionogi Company Information
13.14.2 Shionogi Neurological Drugs Product Portfolios and Specifications
13.14.3 Shionogi Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Shionogi Main Business Overview
13.14.5 Shionogi Latest Developments
13.15 APOTEX
13.15.1 APOTEX Company Information
13.15.2 APOTEX Neurological Drugs Product Portfolios and Specifications
13.15.3 APOTEX Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 APOTEX Main Business Overview
13.15.5 APOTEX Latest Developments
13.16 North China Pharmaceutical
13.16.1 North China Pharmaceutical Company Information
13.16.2 North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 North China Pharmaceutical Main Business Overview
13.16.5 North China Pharmaceutical Latest Developments
13.17 Harbin Pharmaceutical Co., Ltd.
13.17.1 Harbin Pharmaceutical Co., Ltd. Company Information
13.17.2 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
13.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Harbin Pharmaceutical Co., Ltd. Main Business Overview
13.17.5 Harbin Pharmaceutical Co., Ltd. Latest Developments
13.18 Lukang Pharmaceutical
13.18.1 Lukang Pharmaceutical Company Information
13.18.2 Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Lukang Pharmaceutical Main Business Overview
13.18.5 Lukang Pharmaceutical Latest Developments
13.19 Kelun Pharmaceutical
13.19.1 Kelun Pharmaceutical Company Information
13.19.2 Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Kelun Pharmaceutical Main Business Overview
13.19.5 Kelun Pharmaceutical Latest Developments
13.20 Kehua Biology
13.20.1 Kehua Biology Company Information
13.20.2 Kehua Biology Neurological Drugs Product Portfolios and Specifications
13.20.3 Kehua Biology Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Kehua Biology Main Business Overview
13.20.5 Kehua Biology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurological Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Neurological Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Neurological Drugs by Country/Region, 2021, 2025 & 2032
2.2 Neurological Drugs Segment by Type
2.2.1 Non-prescription drugs
2.2.2 Prescription
2.2.3 Neurological Drugs Sales by Type
2.2.3.1 Global Neurological Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Neurological Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Neurological Drugs Sale Price by Type (2021-2026)
2.3 Neurological Drugs Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Neurological Drugs Sales by Application
2.3.3.1 Global Neurological Drugs Sale Market Share by Application (2021-2026)
2.3.3.2 Global Neurological Drugs Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Neurological Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Neurological Drugs Breakdown Data by Company
3.1.1 Global Neurological Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Neurological Drugs Sales Market Share by Company (2021-2026)
3.2 Global Neurological Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Neurological Drugs Revenue by Company (2021-2026)
3.2.2 Global Neurological Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Neurological Drugs Sale Price by Company
3.4 Key Manufacturers Neurological Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurological Drugs Product Location Distribution
3.4.2 Players Neurological Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEUROLOGICAL DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neurological Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Neurological Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Neurological Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Neurological Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Neurological Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Neurological Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Neurological Drugs Sales Growth
4.4 APAC Neurological Drugs Sales Growth
4.5 Europe Neurological Drugs Sales Growth
4.6 Middle East & Africa Neurological Drugs Sales Growth
5 AMERICAS
5.1 Americas Neurological Drugs Sales by Country
5.1.1 Americas Neurological Drugs Sales by Country (2021-2026)
5.1.2 Americas Neurological Drugs Revenue by Country (2021-2026)
5.2 Americas Neurological Drugs Sales by Type (2021-2026)
5.3 Americas Neurological Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurological Drugs Sales by Region
6.1.1 APAC Neurological Drugs Sales by Region (2021-2026)
6.1.2 APAC Neurological Drugs Revenue by Region (2021-2026)
6.2 APAC Neurological Drugs Sales by Type (2021-2026)
6.3 APAC Neurological Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neurological Drugs by Country
7.1.1 Europe Neurological Drugs Sales by Country (2021-2026)
7.1.2 Europe Neurological Drugs Revenue by Country (2021-2026)
7.2 Europe Neurological Drugs Sales by Type (2021-2026)
7.3 Europe Neurological Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurological Drugs by Country
8.1.1 Middle East & Africa Neurological Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Neurological Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Neurological Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Neurological Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurological Drugs
10.3 Manufacturing Process Analysis of Neurological Drugs
10.4 Industry Chain Structure of Neurological Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurological Drugs Distributors
11.3 Neurological Drugs Customer
12 WORLD FORECAST REVIEW FOR NEUROLOGICAL DRUGS BY GEOGRAPHIC REGION
12.1 Global Neurological Drugs Market Size Forecast by Region
12.1.1 Global Neurological Drugs Forecast by Region (2027-2032)
12.1.2 Global Neurological Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Neurological Drugs Forecast by Type (2027-2032)
12.7 Global Neurological Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Neurological Drugs Product Portfolios and Specifications
13.1.3 Pfizer Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Ely Lilly
13.2.1 Ely Lilly Company Information
13.2.2 Ely Lilly Neurological Drugs Product Portfolios and Specifications
13.2.3 Ely Lilly Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Ely Lilly Main Business Overview
13.2.5 Ely Lilly Latest Developments
13.3 Actavis
13.3.1 Actavis Company Information
13.3.2 Actavis Neurological Drugs Product Portfolios and Specifications
13.3.3 Actavis Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Actavis Main Business Overview
13.3.5 Actavis Latest Developments
13.4 Mylan
13.4.1 Mylan Company Information
13.4.2 Mylan Neurological Drugs Product Portfolios and Specifications
13.4.3 Mylan Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Mylan Main Business Overview
13.4.5 Mylan Latest Developments
13.5 Randox
13.5.1 Randox Company Information
13.5.2 Randox Neurological Drugs Product Portfolios and Specifications
13.5.3 Randox Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Randox Main Business Overview
13.5.5 Randox Latest Developments
13.6 Intellipharmaceutics
13.6.1 Intellipharmaceutics Company Information
13.6.2 Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
13.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Intellipharmaceutics Main Business Overview
13.6.5 Intellipharmaceutics Latest Developments
13.7 Astrazeneca
13.7.1 Astrazeneca Company Information
13.7.2 Astrazeneca Neurological Drugs Product Portfolios and Specifications
13.7.3 Astrazeneca Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Astrazeneca Main Business Overview
13.7.5 Astrazeneca Latest Developments
13.8 Lundbeck
13.8.1 Lundbeck Company Information
13.8.2 Lundbeck Neurological Drugs Product Portfolios and Specifications
13.8.3 Lundbeck Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Lundbeck Main Business Overview
13.8.5 Lundbeck Latest Developments
13.9 Allergan
13.9.1 Allergan Company Information
13.9.2 Allergan Neurological Drugs Product Portfolios and Specifications
13.9.3 Allergan Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Allergan Main Business Overview
13.9.5 Allergan Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Neurological Drugs Product Portfolios and Specifications
13.10.3 GSK Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 Otsuka Pharmaceutical
13.11.1 Otsuka Pharmaceutical Company Information
13.11.2 Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Otsuka Pharmaceutical Main Business Overview
13.11.5 Otsuka Pharmaceutical Latest Developments
13.12 Takeda
13.12.1 Takeda Company Information
13.12.2 Takeda Neurological Drugs Product Portfolios and Specifications
13.12.3 Takeda Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Takeda Main Business Overview
13.12.5 Takeda Latest Developments
13.13 NHU Group
13.13.1 NHU Group Company Information
13.13.2 NHU Group Neurological Drugs Product Portfolios and Specifications
13.13.3 NHU Group Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 NHU Group Main Business Overview
13.13.5 NHU Group Latest Developments
13.14 Shionogi
13.14.1 Shionogi Company Information
13.14.2 Shionogi Neurological Drugs Product Portfolios and Specifications
13.14.3 Shionogi Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Shionogi Main Business Overview
13.14.5 Shionogi Latest Developments
13.15 APOTEX
13.15.1 APOTEX Company Information
13.15.2 APOTEX Neurological Drugs Product Portfolios and Specifications
13.15.3 APOTEX Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 APOTEX Main Business Overview
13.15.5 APOTEX Latest Developments
13.16 North China Pharmaceutical
13.16.1 North China Pharmaceutical Company Information
13.16.2 North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 North China Pharmaceutical Main Business Overview
13.16.5 North China Pharmaceutical Latest Developments
13.17 Harbin Pharmaceutical Co., Ltd.
13.17.1 Harbin Pharmaceutical Co., Ltd. Company Information
13.17.2 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
13.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Harbin Pharmaceutical Co., Ltd. Main Business Overview
13.17.5 Harbin Pharmaceutical Co., Ltd. Latest Developments
13.18 Lukang Pharmaceutical
13.18.1 Lukang Pharmaceutical Company Information
13.18.2 Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Lukang Pharmaceutical Main Business Overview
13.18.5 Lukang Pharmaceutical Latest Developments
13.19 Kelun Pharmaceutical
13.19.1 Kelun Pharmaceutical Company Information
13.19.2 Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Kelun Pharmaceutical Main Business Overview
13.19.5 Kelun Pharmaceutical Latest Developments
13.20 Kehua Biology
13.20.1 Kehua Biology Company Information
13.20.2 Kehua Biology Neurological Drugs Product Portfolios and Specifications
13.20.3 Kehua Biology Neurological Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Kehua Biology Main Business Overview
13.20.5 Kehua Biology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neurological Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Neurological Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Non-prescription drugs
Table 4. Major Players of Prescription
Table 5. Global Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 6. Global Neurological Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Neurological Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Neurological Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Neurological Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Neurological Drugs Sale by Application (2021-2026) & (K Units)
Table 11. Global Neurological Drugs Sale Market Share by Application (2021-2026)
Table 12. Global Neurological Drugs Revenue by Application (2021-2026) & ($ million)
Table 13. Global Neurological Drugs Revenue Market Share by Application (2021-2026)
Table 14. Global Neurological Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Neurological Drugs Sales by Company (2021-2026) & (K Units)
Table 16. Global Neurological Drugs Sales Market Share by Company (2021-2026)
Table 17. Global Neurological Drugs Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Neurological Drugs Revenue Market Share by Company (2021-2026)
Table 19. Global Neurological Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Neurological Drugs Producing Area Distribution and Sales Area
Table 21. Players Neurological Drugs Products Offered
Table 22. Neurological Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Neurological Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Neurological Drugs Sales Market Share Geographic Region (2021-2026)
Table 27. Global Neurological Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Neurological Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Neurological Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Neurological Drugs Sales Market Share by Country/Region (2021-2026)
Table 31. Global Neurological Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Neurological Drugs Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Neurological Drugs Sales by Country (2021-2026) & (K Units)
Table 34. Americas Neurological Drugs Sales Market Share by Country (2021-2026)
Table 35. Americas Neurological Drugs Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 37. Americas Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 38. APAC Neurological Drugs Sales by Region (2021-2026) & (K Units)
Table 39. APAC Neurological Drugs Sales Market Share by Region (2021-2026)
Table 40. APAC Neurological Drugs Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 42. APAC Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 43. Europe Neurological Drugs Sales by Country (2021-2026) & (K Units)
Table 44. Europe Neurological Drugs Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 46. Europe Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Neurological Drugs Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Neurological Drugs Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Neurological Drugs
Table 52. Key Market Challenges & Risks of Neurological Drugs
Table 53. Key Industry Trends of Neurological Drugs
Table 54. Neurological Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Neurological Drugs Distributors List
Table 57. Neurological Drugs Customer List
Table 58. Global Neurological Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Neurological Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Neurological Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Neurological Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Neurological Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Neurological Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Neurological Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Neurological Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Neurological Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Neurological Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Neurological Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Neurological Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Neurological Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Neurological Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Neurological Drugs Product Portfolios and Specifications
Table 74. Pfizer Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Ely Lilly Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Ely Lilly Neurological Drugs Product Portfolios and Specifications
Table 79. Ely Lilly Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Ely Lilly Main Business
Table 81. Ely Lilly Latest Developments
Table 82. Actavis Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Actavis Neurological Drugs Product Portfolios and Specifications
Table 84. Actavis Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Actavis Main Business
Table 86. Actavis Latest Developments
Table 87. Mylan Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Mylan Neurological Drugs Product Portfolios and Specifications
Table 89. Mylan Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Mylan Main Business
Table 91. Mylan Latest Developments
Table 92. Randox Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Randox Neurological Drugs Product Portfolios and Specifications
Table 94. Randox Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Randox Main Business
Table 96. Randox Latest Developments
Table 97. Intellipharmaceutics Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
Table 99. Intellipharmaceutics Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Intellipharmaceutics Main Business
Table 101. Intellipharmaceutics Latest Developments
Table 102. Astrazeneca Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Astrazeneca Neurological Drugs Product Portfolios and Specifications
Table 104. Astrazeneca Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Astrazeneca Main Business
Table 106. Astrazeneca Latest Developments
Table 107. Lundbeck Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Lundbeck Neurological Drugs Product Portfolios and Specifications
Table 109. Lundbeck Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Lundbeck Main Business
Table 111. Lundbeck Latest Developments
Table 112. Allergan Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Allergan Neurological Drugs Product Portfolios and Specifications
Table 114. Allergan Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Allergan Main Business
Table 116. Allergan Latest Developments
Table 117. GSK Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. GSK Neurological Drugs Product Portfolios and Specifications
Table 119. GSK Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. GSK Main Business
Table 121. GSK Latest Developments
Table 122. Otsuka Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 124. Otsuka Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Otsuka Pharmaceutical Main Business
Table 126. Otsuka Pharmaceutical Latest Developments
Table 127. Takeda Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Takeda Neurological Drugs Product Portfolios and Specifications
Table 129. Takeda Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Takeda Main Business
Table 131. Takeda Latest Developments
Table 132. NHU Group Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. NHU Group Neurological Drugs Product Portfolios and Specifications
Table 134. NHU Group Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. NHU Group Main Business
Table 136. NHU Group Latest Developments
Table 137. Shionogi Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Shionogi Neurological Drugs Product Portfolios and Specifications
Table 139. Shionogi Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Shionogi Main Business
Table 141. Shionogi Latest Developments
Table 142. APOTEX Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 143. APOTEX Neurological Drugs Product Portfolios and Specifications
Table 144. APOTEX Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. APOTEX Main Business
Table 146. APOTEX Latest Developments
Table 147. North China Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 148. North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 149. North China Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. North China Pharmaceutical Main Business
Table 151. North China Pharmaceutical Latest Developments
Table 152. Harbin Pharmaceutical Co., Ltd. Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 153. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
Table 154. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Harbin Pharmaceutical Co., Ltd. Main Business
Table 156. Harbin Pharmaceutical Co., Ltd. Latest Developments
Table 157. Lukang Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 158. Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 159. Lukang Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Lukang Pharmaceutical Main Business
Table 161. Lukang Pharmaceutical Latest Developments
Table 162. Kelun Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 163. Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 164. Kelun Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Kelun Pharmaceutical Main Business
Table 166. Kelun Pharmaceutical Latest Developments
Table 167. Kehua Biology Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 168. Kehua Biology Neurological Drugs Product Portfolios and Specifications
Table 169. Kehua Biology Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. Kehua Biology Main Business
Table 171. Kehua Biology Latest Developments
Table 1. Neurological Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Neurological Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Non-prescription drugs
Table 4. Major Players of Prescription
Table 5. Global Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 6. Global Neurological Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Neurological Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Neurological Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Neurological Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Neurological Drugs Sale by Application (2021-2026) & (K Units)
Table 11. Global Neurological Drugs Sale Market Share by Application (2021-2026)
Table 12. Global Neurological Drugs Revenue by Application (2021-2026) & ($ million)
Table 13. Global Neurological Drugs Revenue Market Share by Application (2021-2026)
Table 14. Global Neurological Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Neurological Drugs Sales by Company (2021-2026) & (K Units)
Table 16. Global Neurological Drugs Sales Market Share by Company (2021-2026)
Table 17. Global Neurological Drugs Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Neurological Drugs Revenue Market Share by Company (2021-2026)
Table 19. Global Neurological Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Neurological Drugs Producing Area Distribution and Sales Area
Table 21. Players Neurological Drugs Products Offered
Table 22. Neurological Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Neurological Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Neurological Drugs Sales Market Share Geographic Region (2021-2026)
Table 27. Global Neurological Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Neurological Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Neurological Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Neurological Drugs Sales Market Share by Country/Region (2021-2026)
Table 31. Global Neurological Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Neurological Drugs Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Neurological Drugs Sales by Country (2021-2026) & (K Units)
Table 34. Americas Neurological Drugs Sales Market Share by Country (2021-2026)
Table 35. Americas Neurological Drugs Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 37. Americas Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 38. APAC Neurological Drugs Sales by Region (2021-2026) & (K Units)
Table 39. APAC Neurological Drugs Sales Market Share by Region (2021-2026)
Table 40. APAC Neurological Drugs Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 42. APAC Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 43. Europe Neurological Drugs Sales by Country (2021-2026) & (K Units)
Table 44. Europe Neurological Drugs Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 46. Europe Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Neurological Drugs Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Neurological Drugs Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Neurological Drugs Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Neurological Drugs Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Neurological Drugs
Table 52. Key Market Challenges & Risks of Neurological Drugs
Table 53. Key Industry Trends of Neurological Drugs
Table 54. Neurological Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Neurological Drugs Distributors List
Table 57. Neurological Drugs Customer List
Table 58. Global Neurological Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Neurological Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Neurological Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Neurological Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Neurological Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Neurological Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Neurological Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Neurological Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Neurological Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Neurological Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Neurological Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Neurological Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Neurological Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Neurological Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Neurological Drugs Product Portfolios and Specifications
Table 74. Pfizer Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Ely Lilly Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Ely Lilly Neurological Drugs Product Portfolios and Specifications
Table 79. Ely Lilly Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Ely Lilly Main Business
Table 81. Ely Lilly Latest Developments
Table 82. Actavis Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Actavis Neurological Drugs Product Portfolios and Specifications
Table 84. Actavis Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Actavis Main Business
Table 86. Actavis Latest Developments
Table 87. Mylan Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Mylan Neurological Drugs Product Portfolios and Specifications
Table 89. Mylan Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Mylan Main Business
Table 91. Mylan Latest Developments
Table 92. Randox Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Randox Neurological Drugs Product Portfolios and Specifications
Table 94. Randox Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Randox Main Business
Table 96. Randox Latest Developments
Table 97. Intellipharmaceutics Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
Table 99. Intellipharmaceutics Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Intellipharmaceutics Main Business
Table 101. Intellipharmaceutics Latest Developments
Table 102. Astrazeneca Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Astrazeneca Neurological Drugs Product Portfolios and Specifications
Table 104. Astrazeneca Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Astrazeneca Main Business
Table 106. Astrazeneca Latest Developments
Table 107. Lundbeck Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Lundbeck Neurological Drugs Product Portfolios and Specifications
Table 109. Lundbeck Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Lundbeck Main Business
Table 111. Lundbeck Latest Developments
Table 112. Allergan Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Allergan Neurological Drugs Product Portfolios and Specifications
Table 114. Allergan Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Allergan Main Business
Table 116. Allergan Latest Developments
Table 117. GSK Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. GSK Neurological Drugs Product Portfolios and Specifications
Table 119. GSK Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. GSK Main Business
Table 121. GSK Latest Developments
Table 122. Otsuka Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 124. Otsuka Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Otsuka Pharmaceutical Main Business
Table 126. Otsuka Pharmaceutical Latest Developments
Table 127. Takeda Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Takeda Neurological Drugs Product Portfolios and Specifications
Table 129. Takeda Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Takeda Main Business
Table 131. Takeda Latest Developments
Table 132. NHU Group Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. NHU Group Neurological Drugs Product Portfolios and Specifications
Table 134. NHU Group Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. NHU Group Main Business
Table 136. NHU Group Latest Developments
Table 137. Shionogi Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Shionogi Neurological Drugs Product Portfolios and Specifications
Table 139. Shionogi Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Shionogi Main Business
Table 141. Shionogi Latest Developments
Table 142. APOTEX Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 143. APOTEX Neurological Drugs Product Portfolios and Specifications
Table 144. APOTEX Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. APOTEX Main Business
Table 146. APOTEX Latest Developments
Table 147. North China Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 148. North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 149. North China Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. North China Pharmaceutical Main Business
Table 151. North China Pharmaceutical Latest Developments
Table 152. Harbin Pharmaceutical Co., Ltd. Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 153. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
Table 154. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Harbin Pharmaceutical Co., Ltd. Main Business
Table 156. Harbin Pharmaceutical Co., Ltd. Latest Developments
Table 157. Lukang Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 158. Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 159. Lukang Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Lukang Pharmaceutical Main Business
Table 161. Lukang Pharmaceutical Latest Developments
Table 162. Kelun Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 163. Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 164. Kelun Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Kelun Pharmaceutical Main Business
Table 166. Kelun Pharmaceutical Latest Developments
Table 167. Kehua Biology Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 168. Kehua Biology Neurological Drugs Product Portfolios and Specifications
Table 169. Kehua Biology Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. Kehua Biology Main Business
Table 171. Kehua Biology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Neurological Drugs
Figure 2. Neurological Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurological Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Neurological Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Neurological Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Neurological Drugs Sales Market Share by Country/Region (2025)
Figure 10. Neurological Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Non-prescription drugs
Figure 12. Product Picture of Prescription
Figure 13. Global Neurological Drugs Sales Market Share by Type in 2026
Figure 14. Global Neurological Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Neurological Drugs Consumed in Hospital
Figure 16. Global Neurological Drugs Market: Hospital (2021-2026) & (K Units)
Figure 17. Neurological Drugs Consumed in Clinic
Figure 18. Global Neurological Drugs Market: Clinic (2021-2026) & (K Units)
Figure 19. Global Neurological Drugs Sale Market Share by Application (2025)
Figure 20. Global Neurological Drugs Revenue Market Share by Application in 2026
Figure 21. Neurological Drugs Sales by Company in 2026 (K Units)
Figure 22. Global Neurological Drugs Sales Market Share by Company in 2026
Figure 23. Neurological Drugs Revenue by Company in 2026 ($ millions)
Figure 24. Global Neurological Drugs Revenue Market Share by Company in 2026
Figure 25. Global Neurological Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Neurological Drugs Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Neurological Drugs Sales 2021-2026 (K Units)
Figure 28. Americas Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 29. APAC Neurological Drugs Sales 2021-2026 (K Units)
Figure 30. APAC Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 31. Europe Neurological Drugs Sales 2021-2026 (K Units)
Figure 32. Europe Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Neurological Drugs Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 35. Americas Neurological Drugs Sales Market Share by Country in 2026
Figure 36. Americas Neurological Drugs Revenue Market Share by Country (2021-2026)
Figure 37. Americas Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 38. Americas Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 39. United States Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Neurological Drugs Sales Market Share by Region in 2026
Figure 44. APAC Neurological Drugs Revenue Market Share by Region (2021-2026)
Figure 45. APAC Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 46. APAC Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 47. China Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. India Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Neurological Drugs Sales Market Share by Country in 2026
Figure 55. Europe Neurological Drugs Revenue Market Share by Country (2021-2026)
Figure 56. Europe Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 57. Europe Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 58. Germany Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. France Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Neurological Drugs Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 66. Egypt Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Neurological Drugs in 2026
Figure 72. Manufacturing Process Analysis of Neurological Drugs
Figure 73. Industry Chain Structure of Neurological Drugs
Figure 74. Channels of Distribution
Figure 75. Global Neurological Drugs Sales Market Forecast by Region (2027-2032)
Figure 76. Global Neurological Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Neurological Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Neurological Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Neurological Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Neurological Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Neurological Drugs
Figure 2. Neurological Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurological Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Neurological Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Neurological Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Neurological Drugs Sales Market Share by Country/Region (2025)
Figure 10. Neurological Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Non-prescription drugs
Figure 12. Product Picture of Prescription
Figure 13. Global Neurological Drugs Sales Market Share by Type in 2026
Figure 14. Global Neurological Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Neurological Drugs Consumed in Hospital
Figure 16. Global Neurological Drugs Market: Hospital (2021-2026) & (K Units)
Figure 17. Neurological Drugs Consumed in Clinic
Figure 18. Global Neurological Drugs Market: Clinic (2021-2026) & (K Units)
Figure 19. Global Neurological Drugs Sale Market Share by Application (2025)
Figure 20. Global Neurological Drugs Revenue Market Share by Application in 2026
Figure 21. Neurological Drugs Sales by Company in 2026 (K Units)
Figure 22. Global Neurological Drugs Sales Market Share by Company in 2026
Figure 23. Neurological Drugs Revenue by Company in 2026 ($ millions)
Figure 24. Global Neurological Drugs Revenue Market Share by Company in 2026
Figure 25. Global Neurological Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Neurological Drugs Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Neurological Drugs Sales 2021-2026 (K Units)
Figure 28. Americas Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 29. APAC Neurological Drugs Sales 2021-2026 (K Units)
Figure 30. APAC Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 31. Europe Neurological Drugs Sales 2021-2026 (K Units)
Figure 32. Europe Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Neurological Drugs Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Neurological Drugs Revenue 2021-2026 ($ millions)
Figure 35. Americas Neurological Drugs Sales Market Share by Country in 2026
Figure 36. Americas Neurological Drugs Revenue Market Share by Country (2021-2026)
Figure 37. Americas Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 38. Americas Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 39. United States Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Neurological Drugs Sales Market Share by Region in 2026
Figure 44. APAC Neurological Drugs Revenue Market Share by Region (2021-2026)
Figure 45. APAC Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 46. APAC Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 47. China Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. India Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Neurological Drugs Sales Market Share by Country in 2026
Figure 55. Europe Neurological Drugs Revenue Market Share by Country (2021-2026)
Figure 56. Europe Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 57. Europe Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 58. Germany Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. France Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Neurological Drugs Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Neurological Drugs Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Neurological Drugs Sales Market Share by Application (2021-2026)
Figure 66. Egypt Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Neurological Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Neurological Drugs in 2026
Figure 72. Manufacturing Process Analysis of Neurological Drugs
Figure 73. Industry Chain Structure of Neurological Drugs
Figure 74. Channels of Distribution
Figure 75. Global Neurological Drugs Sales Market Forecast by Region (2027-2032)
Figure 76. Global Neurological Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Neurological Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Neurological Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Neurological Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Neurological Drugs Revenue Market Share Forecast by Application (2027-2032)
